Skip to search formSkip to main contentSkip to account menu

EXP 2528

Known as: EXP-2528, EXP2528 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Protective Effect of Compound EXP-2528 on Brain Ischemia-Reperfusion Injury in Rats
OBJECTIVE To investigate the protective effect and preliminary mechanism of compound EXP-2528,a novel AT1 receptor antagonist,on… 
2007
2007
Effect of compound EXP-2528 on angiotensin II-induced E-selectin and VCAM-1 expression in rat brain microvascular endothelial cells in vitro.
The aim of this study is to investigate the effect and mechanism of angiotensin (Ang) II on E-selectin and vascular cell adhesion… 
2006
2006
Angiotensin II stimulates intercellular adhesion molecule-1 via an AT1 receptor/nuclear factor-kappaB pathway in brain microvascular endothelial cells.
Microvascular changes in the brain are significant causes of cerebral edema and ischemia injury. A number of studies suggest that… 
2005
2005
P-448: EXP-2528, a novel angiotensin II type 1 receptor antagonist, protects cerebral microvascular endothelial cells against Angiotensin II injury by antioxidant role
2005
2005
P-447: EXP-2528, a novel angiotensin II type 1 receptor antagonist, protects the brain after transient focal ischemia
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)